Turk, OkanDemirel, NailYaltirik, Cumhur KaanKaya, MustafaSahin, Omer FarukYilmaz, Seda GuelecIsbir, TurgayGenetik ve Biyomühendislik / Genetic and Bio-Engineering2024-05-252024-05-25202400258-851X1791-754910.21873/invivo.134852-s2.0-85186742393https://doi.org/10.21873/invivo.13485https://hdl.handle.net/20.500.14517/1218kaya, mustafa/0000-0001-5548-4944Background/Aim: MicroRNAs (miRNAs) have been identified as key regulators in various cancer types, including brain tumors. This study aimed to investigate the differential expression of miRNA-17 in glial tumors, cerebral metastases, and normal glial tissues. Materials and Methods: A total of 42 patients were included in this cross-sectional study. Tissue samples were obtained from patients with glial tumors or cerebral metastases and from normal glial tissues. miRNA-17 expression levels were computed by using real-time polymerase chain reaction. Receiver operating characteristics analysis was used to determine the predictive potential of miRNA-17. Results: In this study, we demonstrated a statistically significant difference in miRNA-17 expression levels between glial tumors and the control group (p=0.001), with higher miRNA-17 expression observed in glial tumors. Similarly, there was statistically higher miRNA-17 expression in metastatic cases compared with the control group (p=0.007). Conclusion: These findings suggest miRNA-17 might be a potential biomarker for differentiating glial tumors and cerebral metastases from normal glial tissue, although further research is necessary to validate these findings and investigate the potential role of miRNA-17 in the pathogenesis of these brain tumors.eninfo:eu-repo/semantics/openAccessmiRNA-17glial tumorscerebral metastasesmolecular pathogenesisArticleQ4Q3382652656WOS:00117942230000338418125